Zobrazeno 1 - 10
of 425
pro vyhledávání: '"Martin W. Brechbiel"'
Publikováno v:
Translational Oncology, Vol 10, Iss 4, Pp 535-545 (2017)
Identifying molecular targets and an appropriate targeting vehicle, i.e., monoclonal antibodies (mAb) and their various forms, for radioimmunotherapy (RIT) remains an active area of research. Panitumumab, a fully human and less immunogenic mAb that b
Externí odkaz:
https://doaj.org/article/a8c5f71e2dc1422bbd437ec1f5669947
Autor:
Andrew M. Scott, Reinhard von Roemeling, Kosaku Fujiwara, Robert A. Beckman, Martin W. Brechbiel, John M. Mariadason, Anderly C. Chueh, Sylvia Gong, Diana Cao, Dahna Makris, Graeme J. O'Keefe, Glenn A. Cartwright, Fook T. Lee, Ingrid J.G. Burvenich
Supplementary Data - PDF file 92K, Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::852a3739d62e86fd529883a41967447f
https://doi.org/10.1158/1078-0432.22448136
https://doi.org/10.1158/1078-0432.22448136
Autor:
Andrew M. Scott, Reinhard von Roemeling, Kosaku Fujiwara, Robert A. Beckman, Martin W. Brechbiel, John M. Mariadason, Anderly C. Chueh, Sylvia Gong, Diana Cao, Dahna Makris, Graeme J. O'Keefe, Glenn A. Cartwright, Fook T. Lee, Ingrid J.G. Burvenich
Supplementary Figure S3 - PDF file 489K, In vivo saturation of 111In-CHX-A"-DTPA-CS-1008 in WiDr tumors demonstrated by planar gamma camera imaging (A, 0.2 mg/kg; B, 0.5 mg/kg and C, 10 mg/kg). Representative whole body images (left), surface-rendere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6409d21edba8dc16f7e4118d946414
https://doi.org/10.1158/1078-0432.22448127
https://doi.org/10.1158/1078-0432.22448127
Autor:
Andrew M. Scott, Reinhard von Roemeling, Kosaku Fujiwara, Robert A. Beckman, Martin W. Brechbiel, John M. Mariadason, Anderly C. Chueh, Sylvia Gong, Diana Cao, Dahna Makris, Graeme J. O'Keefe, Glenn A. Cartwright, Fook T. Lee, Ingrid J.G. Burvenich
Supplementary Legend - PDF file 77K, Supplementary legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47982d1fe35f00f1ba01eef97b7735de
https://doi.org/10.1158/1078-0432.22448124.v1
https://doi.org/10.1158/1078-0432.22448124.v1
Autor:
Andrew M. Scott, Reinhard von Roemeling, Kosaku Fujiwara, Robert A. Beckman, Martin W. Brechbiel, John M. Mariadason, Anderly C. Chueh, Sylvia Gong, Diana Cao, Dahna Makris, Graeme J. O'Keefe, Glenn A. Cartwright, Fook T. Lee, Ingrid J.G. Burvenich
Purpose: CS-1008 (tigatuzumab; phase I/II), an antihuman death receptor 5 (DR5) agonist, induces apoptosis and has cytotoxic activity against human cancer cell lines. This study reports on the preclinical validation of 111In-labeled anti-DR5 humanize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6fe907746863f253af45a14739532ac
https://doi.org/10.1158/1078-0432.c.6521316.v1
https://doi.org/10.1158/1078-0432.c.6521316.v1
Autor:
Andrew M. Scott, Reinhard von Roemeling, Kosaku Fujiwara, Robert A. Beckman, Martin W. Brechbiel, John M. Mariadason, Anderly C. Chueh, Sylvia Gong, Diana Cao, Dahna Makris, Graeme J. O'Keefe, Glenn A. Cartwright, Fook T. Lee, Ingrid J.G. Burvenich
Supplementary Tables - PDF file 68K, supplementary tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85fee6c23b068b054cad79036af597d7
https://doi.org/10.1158/1078-0432.22448118
https://doi.org/10.1158/1078-0432.22448118
Autor:
Luca Filippi, Martin W. Brechbiel
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 38:209-210
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e38820e32c2e739c10f7fb8c13bb7946
https://doi.org/10.1089/cbr.2022.29014.editorial
https://doi.org/10.1089/cbr.2022.29014.editorial
Publikováno v:
Pharmaceuticals, Vol 8, Iss 3, Pp 435-454 (2015)
The first-in-human phase 1 clinical radioimmunotherapy (RIT) trial with 212Pb-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane-trastuzumab (212Pb-TCMC-trastuzumab) was completed in October 2014 as a joint effort at the University of
Externí odkaz:
https://doaj.org/article/8d01a533ae294f1ba9e03efba8b5dcc1
Autor:
Diane E. Milenic, Alfredo A. Molinolo, María S. Solivella, Eileen Banaga, Julien Torgue, Sarah Besnainou, Martin W. Brechbiel, Kwamena E. Baidoo
Publikováno v:
Pharmaceuticals, Vol 8, Iss 3, Pp 416-434 (2015)
Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate. The objective of this
Externí odkaz:
https://doaj.org/article/bf99e0f8f41e4708a89326e8f90b7985
Autor:
Christie A Canaria, Frank I. Lin, Jeff Buchsbaum, C. Norman Coleman, Charles A. Kunos, Jacek Capala, Michael Graham Espey, Martin W. Brechbiel, Freddy E. Escorcia, Julie A Hong, Deepa Narayanan
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 49:64-72
Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. This article reviews National Cancer Institute (NCI)’s support of RPT thro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a552194bb0d122f4592d7d39c4b3bd0
https://doi.org/10.1007/s00259-021-05503-z
https://doi.org/10.1007/s00259-021-05503-z